Summary
Inhibition of matrix metalloproteinases (MMPs) is an attractive approach to adjuvant therapy in the treatment of cancer. Marimastat is the first orally administered, synthetic MMP inhibitor to be evaluated, in this capacity, in the clinic. Measurement of the rate of change of circulating tumour antigens was used for evaluating biological activity and defining optimum dosage in the early clinical trials of marimastat. Although tumour antigen levels have been used in the clinical management of cancer for many years, they have not been validated as markers of disease progression. In order to investigate the relationship between the effects of marimastat on tumour growth and circulating tumour antigen levels, mice bearing the human gastric tumour, MGLVA1, were treated with marimastat. The MMP inhibitor exerted a significant therapeutic effect, reducing tumour growth rate by 48% (P = 0.0005), and increasing median survival from 19 to 30 days (P = 0.0001). In addition, carcinoembryonic antigen (CEA) levels were measured in serum samples from animals sacrificed at regular intervals, and correlated with excised tumour weight. It was shown that the natural log of the CEA concentration was linearly related to the natural log of the tumour weight and that treatment was not a significant factor in this relationship (P = 0.7). In conclusion, circulating CEA levels were not directly affected by marimastat, but did reflect tumour size. These results support the use of cancer antigens as markers of biological activity in early phase trials of non-cytotoxic anticancer agents.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Allen-Mersh, TG, Kemeny, N, Niedzwiecki, D, Shurgot, B & Daly, JM (1987). Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer. Gut 28: 1625–1629.
Anderson, IC, Shipp, MA, Docherty, AJP & Teicher, BA (1996). Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res 56: 715–718.
Chirivi, RG, Garolafo, A, Crimmin, MJ, Bawden, LJ, Stoppacciaro, A, Brown, PD & Giavazzi, R (1994). Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58: 460–464.
Cottam, DW & Rees, RC (1993). Regulation of matrix metalloproteinases: their role in tumour invasion and metastasis. Int J Oncol 2: 861–872.
Davies, B, Brown, PD, East, N, Crimmin, MJ & Balkwill, FR (1993). A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53: 2087–2091.
D’Errico, A, Garbisa, S, Liotta, LA, Castronovo, V, Stetler-Stevenson, WG & Grigioni, WF (1991). Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric and breast carcinoma progression. Modern Pathol 4: 239–246.
Eccles, SA, Box, GM, Court, WJ, Bone, EA, Thomas, W & Brown, PD (1996). Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 56: 2815–2822.
Giavazzi, R, Garofalo, A, Ferri, A, Lucchini, V, Bone, EA, Chiari, S, Brown, PD, Nicoletti, MI & Taraboletti, G (1998). Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumour activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res 4: 985–992.
Goldenberg, DM, Neville, AM, Carter, AC, Go, VL, Holyoke, ED, Isselbacher, ED, Schein, PS & Schwartz, M (1981). CEA (carcinoembryonic antigen): its role as a marker in the management of cancer. J Cancer Res Clin Oncol 101: 239–242.
Gore, M, A’Hern, R, Stankiewicz, M & Slevin, M (1996). Tumour marker levels during marimastat therapy. Lancet 348: 263
Hida, J, Yasutomi, M, Shindoh, K, Kitaoka, M, Fujimoto, K, Ieda, S, Machidera, N, Kubo, R, Morikawa, E, Inufusa, H, Watatani, M & Okuno, K (1996). Second-look operation for recurrent colorectal cancer based on carcinoembryonic antigen and imaging techniques. Dis Colon Rectum 39: 74–79.
Hine, KR & Dykes, PW (1984). Prospective randomised trial of early cytotoxic therapy for recurrent colorectal carcinoma detected by serum CEA. Gut 25: 682–688.
Hojo, J (1977). Establishment of cultured cell lines of human stomach cancer origin and their morphological characteristics. Niigata Igakukai Zasshi 91: 737
Honda, M, Mori, M, Ueo, H, Sugimachi, K & Akiyoshi, T (1996). Matrix metalloproteinase-7 expression in gastric carcinoma. Gut 39: 444–448.
Kleiner, DE Jr & Stetler-Stevenson, WG (1993). Structural biochemistry and activation of matrix metalloproteinases. Curr Opin Cell Biol 5: 891–897.
Liotta, LA & Stetler-Stevenson, WG (1990). Metalloproteinases and cancer invasion. Sem Cancer Biol 1: 99–106.
Matrisian, LM (1992). The matrix-degrading metalloproteinases. Bioessays 14: 455–463.
McDonnell, S, Navre, M, Coffey, RJ & Matrisian, LM (1991). Expression and localisation of the matrix metalloproteinase Pump-1 (MMP-7) in human gastric and colon carcinoma. Molecular Carcinogenesis 4: 527–533.
Millar, A & Brown, PD (1996). 360 patient meta-analysis of studies of marimastat, a novel matrix metalloproteinase inhibitor. Ann Oncol 7: 123
Millar, A, Brown, P, Cornish, A & Baillet, M (1996). Tumour marker levels during marimastat therapy: reply. Lancet 348: 263–264.
Nemunaitis, J, Poole, C, Primrose, J, Rosemurgy, A, Malfetano, J, Brown, P, Berrington, A, Cornish, A, Lynch, K, Rasmussen, H, Kerr, D, Cox, D & Millar, A (1998). Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumour markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 4: 1101–1109.
NIH Consensus Statement (1981). Carcinoembryonic antigen: its role as a marker in the management of cancer. Br Med J 282: 373–375.
Pimm, MV, Robins, RA & Baldwin, RW (1992). Capture of recombinant ricin A chain by a bispecific anti-RTA: anti-CEA monoclonal antibody pre-targeted to a human gastric carcinoma xenograft in nude mice. J Cancer Res and Clin Oncol 118: 367–370.
Primrose, JN, Bleiberg, H, Daniel, F, Van Belle, S, Mansi, JL, Seymour, M, Johnson, PW, Neoptolomos, JP, Baillet, M, Barker, K, Berrington, A, Brown, PD, Millar, AW & Lynch, KP (1999). Pilot study of oral marimastat in recurrent colorectal cancer: an evaluation of biological activity by measurement of carcinoembryonic antigen. Br J Cancer 79: 509–514.
Sledge, GW Jr, Qulali, M, Goulet, R, Bone, EA & Fife, R (1995). Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 87: 1546–1550.
Stetler-Stevenson, WG, Hewitt, R & Corcoran, M (1996). Matrix metalloproteinases and tumour invasion: from correlation and causality to the clinic. Semin Cancer Biol 7: 147–154.
Taraboletti, G, Garofalo, A, Belotti, D, Drudis, T, Borsotti, P, Scanziani, E, Brown, PD & Giavazzi, R (1995). Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 87: 293–298.
Wang, X, Fu, X, Brown, PD, Crimmin, MJ & Hoffman, RM (1994). Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54: 4726–4728.
Ward, U, Primrose, JN, Finan, PJ, Perren, TJ, Selby, P, Purves, DA & Cooper, EH (1993). The use of tumour markers CEA, CA-129 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer. Br J Cancer 67: 1132–1135.
Watson, SA, Durrant, LG & Morris, DL (1990). The effect of the E2 prostaglandin enprostil, and the somatostatin analogue SMS 201 995, in the growth of a human gastric cell line, MKN45G. Int J Cancer 45: 90–94.
Watson, SA, Durrant, LG, Wencyk, PM, Watson, AL & Morris, DL (1991). Intracellular gastrin in human gastrointestinal tumor cells. J Natl Cancer Inst 83: 866–871.
Watson, SA, Morris, TM, Robinson, G, Crimmin, MJ, Brown, PD & Hardcastle, JD (1995). Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 55: 3629–3633.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Watson, S., Morris, T., Collins, H. et al. Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA. Br J Cancer 81, 19–23 (1999). https://doi.org/10.1038/sj.bjc.6690645
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690645
Keywords
This article is cited by
-
The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities
Nature Reviews Clinical Oncology (2020)
-
Comparative Enzyme Immunoassay of Matrix Metalloproteinases-2, -7, -9 and Their Tissue Inhibitor-2 in Tumors and Plasma of Patients with Gastric Cancer
Bulletin of Experimental Biology and Medicine (2009)
-
Emerging strategies in the treatment of advanced esophageal, gastroesophageal junction, and gastric cancer: the introduction of targeted therapies
Targeted Oncology (2006)
-
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer
British Journal of Cancer (2002)
-
Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial
British Journal of Cancer (2002)